236 related articles for article (PubMed ID: 15770075)
1. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
2. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism.
Kubo M; Koue T; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2007 Oct; 22(5):358-66. PubMed ID: 17965519
[TBL] [Abstract][Full Text] [Related]
4. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males.
Koue T; Kubo M; Funaki T; Fukuda T; Azuma J; Takaai M; Kayano Y; Hashimoto Y
Biol Pharm Bull; 2007 Nov; 30(11):2154-8. PubMed ID: 17978491
[TBL] [Abstract][Full Text] [Related]
5. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole.
Hendset M; Hermann M; Lunde H; Refsum H; Molden E
Eur J Clin Pharmacol; 2007 Dec; 63(12):1147-51. PubMed ID: 17828532
[TBL] [Abstract][Full Text] [Related]
8. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype.
Hendset M; Molden E; Knape M; Hermann M
Ther Drug Monit; 2014 Feb; 36(1):80-5. PubMed ID: 24232129
[TBL] [Abstract][Full Text] [Related]
10. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
[TBL] [Abstract][Full Text] [Related]
12. The effect of coadministration of duloxetine on steady-state serum concentration of risperidone and aripiprazole: a study based on therapeutic drug monitoring data.
Hendset M; Molden E; Enoksen TB; Refsum H; Hermann M
Ther Drug Monit; 2010 Dec; 32(6):787-90. PubMed ID: 21068650
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
[TBL] [Abstract][Full Text] [Related]
14. Impact of age and CYP2D6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status.
Tveito M; Molden E; Høiseth G; Correll CU; Smith RL
Eur J Clin Pharmacol; 2020 Jan; 76(1):41-49. PubMed ID: 31637453
[TBL] [Abstract][Full Text] [Related]
15. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Lisbeth P; Vincent H; Kristof M; Bernard S; Manuel M; Hugo N
Eur J Clin Pharmacol; 2016 Feb; 72(2):175-84. PubMed ID: 26514968
[TBL] [Abstract][Full Text] [Related]
16. Stereochemical aspects of itraconazole metabolism in vitro and in vivo.
Kunze KL; Nelson WL; Kharasch ED; Thummel KE; Isoherranen N
Drug Metab Dispos; 2006 Apr; 34(4):583-90. PubMed ID: 16415110
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes.
Kneller LA; Abad-Santos F; Hempel G
Clin Pharmacokinet; 2020 Jan; 59(1):51-65. PubMed ID: 31359271
[TBL] [Abstract][Full Text] [Related]
18. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service.
Castberg I; Spigset O
Pharmacopsychiatry; 2007 May; 40(3):107-10. PubMed ID: 17541885
[TBL] [Abstract][Full Text] [Related]
19. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
[TBL] [Abstract][Full Text] [Related]
20. Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers.
Koller D; Belmonte C; Saiz-Rodríguez M; Zubiaur P; Román M; Ochoa D; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):236-246. PubMed ID: 31520576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
